Company Overview and News

 
Gammon Infrastructure Projects Limited - Shareholders meeting

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Shareholders meeting

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Updates

2018-09-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Shareholders meeting

2018-08-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Financial Result Updates

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

4
Podcast | Trade war fears grips equity markets across the globe; Nifty ends below 10,950

2018-07-11 moneycontrol
Bucking the global trend, Nifty managed to close in positive compared to muted performance seen in other Asian markets amid fears of trade wars between US and China.
BAJAJ-AUTO 532959 IDBI 532977 TTNQY 533278 532215 500470 532540 AXISBANK 500570 TATAMOTORS CLNDY V2RETAIL 500116 AXB IBN 532867 AXBKY AXBA ICICIBANK GAMMNINFRA TTST TATASTEEL TATLY 532174 TCS COALINDIA TTM

4
An evening walk down Dalal Street: Trade war fears grips equity markets across the globe; Nifty ends below 10,950

2018-07-11 moneycontrol
Bucking the global trend, Nifty managed to close in positive compared to muted performance seen in other Asian markets amid fears of trade wars between US and China.
BAJAJ-AUTO 532959 IDBI 532977 TTNQY 533278 532215 500470 532540 AXISBANK 500570 TATAMOTORS CLNDY V2RETAIL 500116 AXB IBN 532867 AXBKY AXBA ICICIBANK GAMMNINFRA TTST TATASTEEL TATLY 532174 TCS COALINDIA TTM

 
Gammon Infra locked at 5% lower circuit on termination of concession pact with APRDC

2018-07-11 moneycontrol
Shares of Gammon Infrastructure Projects has locked at 5 percent lower circuit on termination of contract with APRDC.
UBNC GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Updates

2018-07-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

11
Brookfield to sharpen focus on renewable energy sector in India

2018-06-28 livemint
Mumbai: Canada-based Brookfield Asset Management Inc. is looking to increase its focus on renewable energy in India, said two people aware of the firm’s plans, on the condition of anonymity. The asset manager has so far been focussing largely on the real estate and roads segment.
GAMMNINFRA MIC 532959 GLBL BEP

 
Gammon Infrastructure Projects Limited - Financial Result Updates

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

 
Gammon Infrastructure Projects Limited - Change in Director(s)

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GAMMNINFRA 532959

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

7h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...